STOCK TITAN

Soligenix Inc - SNGX STOCK NEWS

Welcome to our dedicated page for Soligenix news (Ticker: SNGX), a resource for investors and traders seeking the latest updates and insights on Soligenix stock.

Overview

Soligenix Inc (SNGX) is a late-stage biopharmaceutical company based in the United States that specializes in developing and commercializing innovative products addressing unmet medical needs. With a focus on orphan diseases, inflammation, oncology, and biodefense, the company leverages advanced technologies to create therapeutics and vaccine candidates designed for rare and niche medical conditions.

Business Segments and Product Portfolio

Soligenix operates two distinct business segments:

  • Specialized BioTherapeutics: This segment is dedicated to developing novel therapies for rare disorders and orphan diseases. Among its flagship programs is a photodynamic therapy that employs synthetic hypericin for the treatment of cutaneous T-cell lymphoma (CTCL). The company utilizes safe, visible light activation to trigger the therapeutic effects of its compounds, thereby reducing the risks associated with traditional treatments.
  • Public Health Solutions: Focused on biodefense and vaccine development, this segment includes programs to develop vaccines for ricin toxin exposure, filovirus infections such as those caused by Ebola and Marburg viruses, and other emerging infectious diseases. The development of thermostabilized vaccine formulations via its proprietary technology platform enhances their resilience and accessibility even in challenging storage environments.

Innovative Therapeutic Approaches

At its core, Soligenix is an innovator in biopharmaceutical research. The company’s approach emphasizes:

  • Orphan Drug Focus: Addressing diseases with significant unmet medical needs, ensuring that even rare conditions receive the focus required for treatment breakthroughs.
  • Advanced Photodynamic Therapy: Through programs such as HyBryte, Soligenix demonstrates the effective use of synthetic hypericin combined with visible light activation. This method offers a potent, targeted treatment for CTCL, minimizing systemic exposure and potential side effects inherent in conventional treatments.
  • Heat-Stabilized Vaccine Platforms: Utilizing a unique combination of GRAS excipients and lyophilization, the company manufactures vaccines that are stable at ambient temperatures, a critical factor for both military and civilian biodefense applications.

Market Position and Competitive Landscape

Operating within a highly specialized niche, Soligenix distinguishes itself with its dual focus on orphan therapeutics and biodefense. The company continues to advance clinical trials with clear protocols and has secured orphan drug and fast track designations from prominent regulatory authorities. By leveraging government grants and non-dilutive funding, Soligenix is well positioned to overcome the challenges associated with clinical validation and commercialization in competitive markets.

Intellectual Property and Strategic Collaborations

Soligenix has built a robust intellectual property portfolio that encompasses novel synthesis methods and treatments for rare diseases. Strategic manufacturing collaborations further enhance its capabilities in scaling production and ensuring quality, critical factors for commercial success. These alliances help solidify its market role and support ongoing research, clinical trials, and regulatory activities.

Commitment to Unmet Medical Needs

The company is unwavering in its commitment to provide therapies where options are limited. Whether it is through innovative photodynamic treatment for CTCL or next-generation vaccine platforms aimed at biodefense, Soligenix prioritizes technological advancement and patient safety. The detailed clinical trial programs and continuous research efforts underscore its expertise and dedication within the biopharmaceutical field.

Conclusion

In summary, Soligenix Inc establishes its significance through a combination of advanced scientific methodologies and a focused strategy on rare diseases with high unmet needs. Its dual business segments not only contribute to a diversified product pipeline but also reinforce its authorization as a relevant player in the competitive biopharmaceutical landscape. Investors and industry experts can view Soligenix as a company that merges solid clinical data with a strategic vision for addressing health challenges that many others overlook.

Rhea-AI Summary

Soligenix announced significant progress in its Phase 3 FLASH study of SGX301 for treating cutaneous T-cell lymphoma (CTCL). Continued treatment for 6 months showed a 49% response rate, increasing from 40% in the previous cycle. Key findings include effective treatment of both patch and plaque lesions, with 66% of patients opting for extended therapy. The drug's safety profile remains robust, with no systemic hypericin detected. Soligenix is preparing for FDA application while targeting commercialization or partnerships for SGX301, emphasizing its potential as a transformative therapy.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

Soligenix, a late-stage biopharmaceutical company, announced that Christopher J. Schaber, Ph.D., its CEO, will present at the BIO Investor Forum from October 13-15, 2020. The presentation will be available on-demand for attendees. Soligenix focuses on developing products for rare diseases, including SGX301 for cutaneous T-cell lymphoma and dusquetide for oral mucositis in head and neck cancer. Their Public Health Solutions segment includes a ricin toxin vaccine and other vaccine candidates for emerging infectious diseases. For more details, visit www.soligenix.com.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.64%
Tags
conferences
-
Rhea-AI Summary

Soligenix, Inc. (Nasdaq: SNGX) announced the publication of nonclinical results on filovirus protein antigens, including for Ebola and Marburg viruses, revealing successful thermostabilization. Collaborative research with the University of Colorado and University of Hawaiʻi at Mānoa indicates that heat-stable vaccine formulations can be developed, maintaining stability for 12 weeks at 40°C. The company aims to expedite its Marburg virus vaccine evaluations. This advancement aligns with their joint COVID-19 vaccine effort, CiVax™, to enhance vaccine distribution reliability in regions with unstable power supplies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary

Soligenix, Inc. (Nasdaq: SNGX) hosted an investor webcast on September 10, 2020, showcasing its COVID-19 vaccine candidate, CiVax™, developed from its thermostabilized glycoprotein vaccine platform. Collaborating with the University of Hawaiʻi, the platform focuses on multivalent vaccines, showing potential for broad applicability, particularly for vulnerable populations. Preclinical results indicate strong immune responses following vaccination. The company aims to address urgent needs for effective COVID-19 prevention amidst the pandemic.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.16%
Tags
covid-19
-
Rhea-AI Summary

Soligenix, Inc. (Nasdaq: SNGX), a late-stage biopharmaceutical company, announces that its CEO, Christopher J. Schaber, PhD, will present at two upcoming virtual investor conferences. The first is the Cantor Virtual Global Healthcare Conference on September 15, 2020, at 1:20 PM ET, with a live presentation available online. The second is the Lake Street Capital Markets' 4th Annual Best Ideas Growth Conference on September 17, 2020, which includes one-on-one and group meetings. Soligenix focuses on developing treatments for rare diseases and has multiple ongoing programs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.56%
Tags
conferences
-
Rhea-AI Summary

Soligenix, Inc. (SNGX) announced an Investor Webcast Event on September 10, 2020, to discuss its CiVax™ COVID-19 vaccine development using a thermostabilized glycoprotein platform. The prototype vaccine demonstrates strong immunity induction in preclinical studies, with notable safety in high-risk populations. Combined with its ability to remain stable at high temperatures, CiVax™ aims to meet urgent vaccination needs. Experts will present, followed by a Q&A session. The event invites questions beforehand and will provide a recording post-webcast.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.13%
Tags
covid-19
Rhea-AI Summary

Soligenix, Inc. (Nasdaq: SNGX), a biopharmaceutical company focused on rare diseases, announced that its CFO, Jonathan Guarino, will present at the LD Micro Conference from September 1-4, 2020. Guarino's presentation is scheduled for September 4 at 9:40 AM ET. The conference will be held virtually. The company specializes in developing treatments like SGX301 for cutaneous T-cell lymphoma and vaccine candidates for various diseases. For more details on the conference, visit LD Micro Conference.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.47%
Tags
conferences
-
Rhea-AI Summary

Soligenix, Inc. (SNGX) announced its Q2 2020 financial results and recent accomplishments. Revenue was $0.5 million, down from $1.4 million in Q2 2019. Net loss increased to $2.8 million, or ($0.10) per share, primarily due to higher R&D costs ($2.2 million). Positive developments include significant results from the Phase 3 FLASH trial for SGX301, with a statistically significant treatment response (p=0.04). Enrollment was completed for the SGX942 trial, with top-line results expected in Q4 2020. The company maintains a cash position of approximately $11.2 million, bolstered by government funding.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.93%
Tags
-
Rhea-AI Summary

Soligenix, Inc. (SNGX) announced positive results from pre-clinical studies for its CiVax™ COVID-19 vaccine, demonstrating rapid onset immunity with antibody responses detected within 14 days of vaccination. Collaborations with the University of Hawaiʻi at Mānoa highlighted the efficacy of the CoVaccine HT™ adjuvant in enhancing immune responses. The vaccine aims to simplify distribution by being heat stable, which could alleviate cold chain logistics. The findings have been submitted for peer review in the journal npj Vaccines, reinforcing Soligenix's commitment to developing safe and effective vaccines for COVID-19.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
22.54%
Tags
clinical trial covid-19
Rhea-AI Summary

Soligenix has completed patient enrollment for its Phase 3 DOM-INNATE study of SGX942, targeting oral mucositis in head and neck cancer patients. A total of 268 subjects were enrolled following positive interim analysis by an independent Data Monitoring Committee (DMC), which confirmed a beneficial drug effect. With top-line results expected in Q4 2020, SGX942 aims to address a significant unmet need as no FDA-approved treatment currently exists for this condition. The company maintains approximately $8 million in cash, positioning for further development milestones.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.89%
Tags

FAQ

What is the current stock price of Soligenix (SNGX)?

The current stock price of Soligenix (SNGX) is $1.84 as of April 4, 2025.

What is the market cap of Soligenix (SNGX)?

The market cap of Soligenix (SNGX) is approximately 6.5M.

What is the core focus of Soligenix Inc?

Soligenix Inc is focused on developing and commercializing innovative therapeutics and vaccines targeting rare diseases with significant unmet medical needs, particularly in oncology, inflammation, and biodefense.

How does Soligenix generate revenue?

The company primarily generates revenue through government contracts, grants, and milestone-based funding tied to its clinical trial successes and ongoing development programs within its specialized and public health segments.

What are the main business segments of Soligenix?

Soligenix operates two main segments: Specialized BioTherapeutics, which develops treatments for orphan diseases such as CTCL, and Public Health Solutions, which focuses on biodefense-related vaccine development.

What therapeutic areas does Soligenix focus on?

The company targets multiple therapeutic areas including cutaneous T-cell lymphoma (CTCL), orphan diseases, inflammatory conditions, and biodefense, with products designed to address both clinical and public health challenges.

How does HyBryte™ differentiate itself in treating CTCL?

HyBryte™ employs a novel photodynamic therapy using synthetic hypericin activated by safe, visible light, offering targeted treatment with minimal systemic exposure and a favorable safety profile compared to traditional therapies.

What role does intellectual property play for Soligenix?

Soligenix has established a robust portfolio of patents covering novel synthesis methods and therapeutic applications, which strengthens its competitive position and supports its advanced clinical programs.

How is the company supported financially?

Soligenix benefits from government grants, non-dilutive funding, and strategic partnerships, allowing it to progress in clinical trials and product development while mitigating financial risk.

What are the key technologies used in Soligenix's vaccine programs?

The company uses a proprietary heat stabilization platform, ThermoVax®, which employs GRAS excipients and lyophilization to produce vaccines that are stable at ambient temperatures, enhancing their practical use in biodefense.
Soligenix Inc

Nasdaq:SNGX

SNGX Rankings

SNGX Stock Data

6.47M
3.15M
0.03%
1.22%
4.01%
Biotechnology
Pharmaceutical Preparations
Link
United States
PRINCETON